BlackRock’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5,994,276
| Closed | -$94.3M | – | 5387 |
|
|
2024
Q1 | $94.3M | Buy |
5,994,276
+18,010
| +0.3% | +$277K | ﹤0.01% | 2084 |
|
|
2023
Q4 | $96.4M | Buy |
5,976,266
+527,260
| +10% | +$6.73M | ﹤0.01% | 2101 |
|
|
2023
Q3 | $69.3M | Sell |
5,449,006
-18,993
| -0.3% | -$262K | ﹤0.01% | 2201 |
|
|
2023
Q2 | $77M | Sell |
5,467,999
-76,989
| -1% | -$1.1M | ﹤0.01% | 2222 |
|
|
2023
Q1 | $85.7M | Buy |
5,544,988
+124,963
| +2% | +$2.09M | ﹤0.01% | 2107 |
|
|
2022
Q4 | $88.8M | Buy |
5,420,025
+208,162
| +4% | +$3.38M | ﹤0.01% | 2075 |
|
|
2022
Q3 | $96.4M | Sell |
5,211,863
-316,879
| -6% | -$4.97M | ﹤0.01% | 1993 |
|
|
2022
Q2 | $72.7M | Buy |
5,528,742
+683,366
| +14% | +$7.54M | ﹤0.01% | 2238 |
|
|
2022
Q1 | $44.9M | Buy |
4,845,376
+1,047,807
| +28% | +$8.91M | ﹤0.01% | 2648 |
|
|
2021
Q4 | $37.1M | Buy |
3,797,569
+102,664
| +3% | +$1.93M | ﹤0.01% | 2871 |
|
|
2021
Q3 | $126M | Buy |
3,694,905
+13,692
| +0.4% | +$437K | ﹤0.01% | 2077 |
|
|
2021
Q2 | $135M | Buy |
3,681,213
+196,210
| +6% | +$7.6M | ﹤0.01% | 2071 |
|
|
2021
Q1 | $156M | Buy |
3,485,003
+75,145
| +2% | +$3.5M | ﹤0.01% | 1895 |
|
|
2020
Q4 | $195M | Buy |
3,409,858
+150,286
| +5% | +$8.91M | 0.01% | 1642 |
|
|
2020
Q3 | $167M | Buy |
3,259,572
+170,366
| +6% | +$8.35M | 0.01% | 1525 |
|
|
2020
Q2 | $184M | Buy |
3,089,206
+962,105
| +45% | +$51.5M | 0.01% | 1426 |
|
|
2020
Q1 | $87.6M | Buy |
2,127,101
+108,024
| +5% | +$6M | ﹤0.01% | 1736 |
|
|
2019
Q4 | $126M | Sell |
2,019,077
-2,391
| -0.1% | -$114K | ﹤0.01% | 1818 |
|
|
2019
Q3 | $68.6M | Buy |
2,021,468
+489,624
| +32% | +$14.5M | ﹤0.01% | 2105 |
|
|
2019
Q2 | $34.5M | Buy |
1,531,844
+311,870
| +26% | +$7.3M | ﹤0.01% | 2544 |
|
|
2019
Q1 | $28.3M | Buy |
1,219,974
+46,729
| +4% | +$1.22M | ﹤0.01% | 2583 |
|
|
2018
Q4 | $24.6M | Buy |
1,173,245
+497,427
| +74% | +$12.2M | ﹤0.01% | 2604 |
|
|
2018
Q3 | $26.2M | Buy |
675,818
+84,754
| +14% | +$3.13M | ﹤0.01% | 2728 |
|
|
2018
Q2 | $23.3M | Buy |
591,064
+91,185
| +18% | +$2.68M | ﹤0.01% | 2772 |
|
|
2018
Q1 | $10M | Buy |
499,879
+136,396
| +38% | +$3.45M | ﹤0.01% | 3129 |
|
|
2017
Q4 | $8.24M | Buy |
363,483
+354,595
| +3,990% | +$6.94M | ﹤0.01% | 3245 |
|
|
2017
Q3 | $169K | Buy |
+8,888
| New | +$163K | ﹤0.01% | 4261 |
|
Other funds holding DCPH
BlackRock's DCPH Position: Q2 2024 in Review
BlackRock sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 5,994,276 shares — an estimated $94.3M sold.
BlackRock first reported a position in DCPH in Q3 2017 and held it in 27 quarters. The position peaked at $195M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- BlackRock reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 5,994,276 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $94.3M.
- BlackRock first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 27 quarters.
- BlackRock's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $195M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.